Heron Therapeutics (HRTX) Q2 FY26 earnings call

Heron Therapeutics reported mixed Q2 FY26 results, with acute care products Zynrelef and Aponvy showing growth, though overall revenue fell short of internal targets. The company is actively responding to a recent court decision impacting Sinvanti's patent outlook, which has prompted a balance sheet reset, tightened spending, and a formal review of strategic alternatives. Management has withdrawn its full-year guidance due to the increased market uncertainties surrounding potential generic entry and ongoing strategic considerations.